These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 34349236)
1. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. Wang L; Wu Y; Yao S; Ge H; Zhu Y; Chen K; Chen WZ; Zhang Y; Zhu W; Wang HY; Guo Y; Ma PX; Ren PX; Zhang XL; Li HQ; Ali MA; Xu WQ; Jiang HL; Zhang LK; Zhu LL; Ye Y; Shang WJ; Bai F Acta Pharmacol Sin; 2022 Apr; 43(4):788-796. PubMed ID: 34349236 [TBL] [Abstract][Full Text] [Related]
2. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
3. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
4. Withanone from Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804 [TBL] [Abstract][Full Text] [Related]
5. Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19. Ma LL; Liu HM; Liu XM; Yuan XY; Xu C; Wang F; Lin JZ; Xu RC; Zhang DK Eur J Med Chem; 2021 Dec; 226():113857. PubMed ID: 34628234 [TBL] [Abstract][Full Text] [Related]
6. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides. Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962 [TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries. David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A Molecules; 2021 May; 26(11):. PubMed ID: 34072087 [TBL] [Abstract][Full Text] [Related]
8. Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor. Kim YS; Kim B; Kwon EB; Chung HS; Choi JG Nutrients; 2022 Oct; 14(19):. PubMed ID: 36235822 [TBL] [Abstract][Full Text] [Related]
9. A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor. Rajpoot S; Ohishi T; Kumar A; Pan Q; Banerjee S; Zhang KYJ; Baig MS Drugs R D; 2021 Sep; 21(3):273-283. PubMed ID: 34324175 [TBL] [Abstract][Full Text] [Related]
10. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study. Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454 [TBL] [Abstract][Full Text] [Related]
11. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor. Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310 [TBL] [Abstract][Full Text] [Related]
12. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). Nayak SK Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074 [TBL] [Abstract][Full Text] [Related]
14. An Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364 [TBL] [Abstract][Full Text] [Related]
15. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2. Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070 [TBL] [Abstract][Full Text] [Related]
17. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites. Qiao B; Olvera de la Cruz M ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067 [TBL] [Abstract][Full Text] [Related]
18. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480 [TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2. Ohishi T; Hishiki T; Baig MS; Rajpoot S; Saqib U; Takasaki T; Hara Y PLoS One; 2022; 17(7):e0271112. PubMed ID: 35830431 [TBL] [Abstract][Full Text] [Related]
20. Discovery of a Natural Product with Potent Efficacy Against SARS-CoV-2 by Drug Screening. Li D; Wang C; Wang S; Mehmood A; Gu J; Cheng X; Chen P; Qiu J; Zhao J; Wang J; Wei D Interdiscip Sci; 2022 Mar; 14(1):55-63. PubMed ID: 34510373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]